Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 87.8%

Neg 87.8% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.